

**Title : Certificate of Analysis Finished Product**

|                     |                                  |                        |              |
|---------------------|----------------------------------|------------------------|--------------|
| <b>Product Name</b> | AZIDIME Injection                | <b>A.R. No.</b>        | BD/FP/24/367 |
| <b>Generic Name</b> | Ceftazidime for Injection IP 1gm | <b>Sampled qty.</b>    | 45 Vials     |
| <b>Batch No.</b>    | B24351D                          | <b>Sampled by</b>      | Vineet       |
| <b>Batch Size</b>   | 7000 Vials                       | <b>Sampled on</b>      | 19/10/2024   |
| <b>Mfg. Date</b>    | 10/2024                          | <b>Date of Testing</b> | 19/10/2024   |
| <b>Exp. Date</b>    | 09/2026                          | <b>Date of Release</b> | 04/11/2024   |

| S. No. | Tests                               | Specifications   | Observations                                   |
|--------|-------------------------------------|--|--|
| 1.     | Description                         | A white dry powder filled in clear glass vial.   | A white dry powder filled in clear glass vial. |
| 2.     | Identification (By HPLC)            | In, assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the working standard solution.                 | Complies                                       |
| 3.     | Uniformity of Weight                | Average weight $\pm 10\%$  | -0.65% & +0.72%                                |
| 4.     | Average weight                      | Informative.   | 1303.7 mg                                      |
| 5.     | pH                                  | 5.0 to 7.5   | 6.48   |
| 6.     | Loss On Drying                      | NMT- 13.5%   | 10.43%   |
| 7.     | Particulate Matter                  |  |  |
|        | (a.) Sub-Visible particle count     |  |  |
|        | (1.) Particles $\geq 10\mu\text{m}$ | NMT-6000/vial  | 110/vial                                       |
|        | (2.) Particles $\geq 25\mu\text{m}$ | NMT-600/vial   | 34/vial  |
|        | (b.) Visual                         | The solution should be essentially free from extraneous, mobile undissolved particles, other than gas bubbles, unintentionally.  | Complies                                       |
| 8.     | Pyridine                            | NMT- 0.4%  | Complies                                       |
| 9.     | Sodium Carbonate (By AAS)           | Weight accurately a quantity containing about 50mg of anhydrous Ceftazidime and dissolve in sufficient water to produce 100.00 ml. Dilute the resulting solution appropriately with water. | Complies                                       |
| 10.    | Sterility                           | No microbial growth should be observed.  | Complies                                       |
| 11.    | Bacterial Endotoxins                | NMT- 0.10 EU/mg of Ceftazidime.  | Less than- 0.10 EU/mg of Ceftazidime.          |
| 12.    | Assay<br>Each vial Contains :       |  |  |

Analysis by  Checked by  Approved by 



**Title : Certificate of Analysis Finished Product**

|              |                                  |                 |              |
|--------------|----------------------------------|-----------------|--------------|
| Product Name | AZIDIME Injection                | A.R. No.        | BD/FP/24/367 |
| Generic Name | Ceftazidime for Injection IP 1gm | Sampled qty.    | 45 Vials     |
| Batch No.    | B24351D                          | Sampled by      | Vineet       |
| Batch Size   | 7000 Vials                       | Sampled on      | 19/10/2024   |
| Mfg. Date    | 10/2024                          | Date of Testing | 19/10/2024   |
| Exp. Date    | 09/2026                          | Date of Release | 04/11/2024   |

| Ingredients   | Labeled Claim | Found     | % of labeled amount | Limits % of labeled amount |
|---|---------------|-----------|---------------------|----------------------------|
| Ceftazidime (Sterile) IP<br>Eq. to anhydrous Ceftazidime<br>(a sterile mixture of Ceftazidime & Sodium Carbonate) | 1000 mg       | 988.75 mg | 98.88%              | 90.0 to 105.0%             |

**Remarks: In the opinion of the undersigned the sample referred to above is/ is not of the standard quality as The Drug & Cosmetic Act 1940 and the rules made there under. Complies/ not-complies as per IP/BP/USP/PHS.**

Analysis by  Checked by  Approved by 

